RLY-2608 is an investigational allosteric pan-mutant PI3Kα inhibitor. It is being developed to treat cancers with PIK3CA mutations, including breast and gynecologic cancers. Unlike earlier PI3K inhibitors, it aims for mutant selectivity, reducing toxicity. Currently under clinical trials, not yet FDA-approved. The directory classifies it as a clinical API with a synthetic source/manufacturing origin. Other names for this substance include Zovegalisib and Pan-mutant PI3Ka Inhibitor RLY-2608. Its PubChem CID is 166822065.
Rly-2608
| CAS No | 2733573-94-7 |
|---|---|
| Molecular Formula | C29H14ClF5N6O2 |
| Molecular Weight | 608.9 g/mol |
| Synonyms | N-[(3R)-3-(2-chloro-5-fluorophenyl)-6-(5-cyano-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-oxo-2,3-dihydroisoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
RLY-2608 is an investigational allosteric pan-mutant PI3Kα inhibitor. It is being developed to treat cancers with PIK3CA mutations, including breast and gynecologic cancers.
The listed CAS number is 2733573-94-7.
The listed molecular formula is C29H14ClF5N6O2.
The listed molecular weight is 608.9 g/mol.
N-[(3R)-3-(2-chloro-5-fluorophenyl)-6-(5-cyano-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-oxo-2,3-dihydroisoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide.
The source lists Zovegalisib and Pan-mutant PI3Ka Inhibitor RLY-2608.